This research study is studying a targeted therapy known as GO-203-2C as a possible treatment for with acute myeloid leukemia (AML) both alone and in combination with decitabine. GO-203-2c targets cancer cells, while leaving healthy cells unaffected.This is a Phase I/II clinical trial. A Phase I clinical trial tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies.

Start Date01 Sep 2014

Sponsor / Collaborator

Beth Israel Deaconess Medical Center, Inc.

[+1]

NCT01279603 / CompletedPhase 1

A Phase 1, Multi-center, Open-label, Dose-escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GO-203-2c Given Intravenously Daily X21 Repeated Every 28 Days in Patients With Advanced Solid Tumors Including Lymphomas

This clinical trial is about testing GO-203-2c, which is a newly discovered compound that binds to an oncoprotein (a cancer causing protein) called MUC1 (which is over-expressed in many cancers). By binding to MUC1, GO-203-2c eventually causes tumor cell death in laboratory studies.
This study is being done to:
Test the safety of GO-203-2c and see what effects (good and bad) it has on you and your cancer
Find the highest dose of GO-203-2c that can be given without causing bad side effects
Examine how much GO-203-2c is in the blood at certain times after it is given and how quickly the body gets rid of it
Observe whether there is any effect of GO-203-2c on the size and activity of cancer in your body

Start Date01 Jan 2011

Sponsor / Collaborator

Genus Oncology LLC

NCT02658396 / WithdrawnPhase 1IIT

A Phase I Trial of the MUC1 Inhibitor, GO-203-2c, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

This research study is studying a combination of targeted therapies known as GO-203-2C and bortezomib as a possible treatment for multiple myeloma that has either progressed or not responded to treatment.

Start Date-

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+2]

100 Clinical Results associated with GO-2032c

100 Translational Medicine associated with GO-2032c

100 Patents (Medical) associated with GO-2032c

100 Deals associated with GO-2032c

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15008

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia	Phase 2	US	Dana-Farber Cancer Institute, Inc.	25 Aug 2014
Plasma cell myeloma refractory	Phase 1	US	Genus Oncology LLC	18 Jan 2016
Relapse multiple myeloma	Phase 1	US	Genus Oncology LLC	18 Jan 2016
Advanced Malignant Solid Neoplasm	Phase 1	US	Genus Oncology LLC	01 Jan 2011
Lymphoma	Phase 1	US	Genus Oncology LLC	01 Jan 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis